CKD Pharmacotherapy: How Renal Dosing Changed With New Anti-Diabetic and Anti-Obesity Agents
- 0:00 Why Dosing Changed
- 8:00 Measures That Matter
- 16:00 SGLT2 Inhibitors In CKD
Practical shifts you can apply this week
-
Identify Which Newer Anti-Diabetic And Anti-Obesity Agents Require Renal Dose Ad
Leave with clearer prescribing calls by CKD stage, including when to monitor more closely or stop.
-
Compare How SGLT2 Inhibitors, GLP-1 Receptor Agonists, Dual Incretin Agents, Ins
See where glycemic effect fades, where cardiorenal benefit remains, and where hypoglycemia risk quietly rises.
-
Evaluate When Cardiorenal Benefit Should Outweigh Glucose-Centric Thinking In Me
Make treatment choices that fit kidney and CV risk, not just the A1C line on the lab sheet.
-
Apply A Practical Prescribing Framework To Initiation, Titration, Sick-Day Manag
Use a stepwise approach for starts, dose changes, pauses during illness, and common safety issues.
-
Draft A Medication Review Plan That Aligns Renal Function, Comorbidity Burden, A
Turn a messy med list into a focused review plan you can use in clinic the next day.
What we'll cover
-
0:00
Why Dosing Changed
Why glucose-first habits miss the mark in CKD, and how newer agents changed the treatment goal.
-
8:00
Measures That Matter
Using eGFR, albuminuria, volume status, acute illness, and dialysis context without oversimplifying.
-
16:00
SGLT2 Inhibitors In CKD
Initiation, continuation, expected eGFR dip, sick-day rules, and why less glucose effect does not mean less value.
-
28:00
GLP-1 And Dual Incretins
Renal dosing patterns, GI toxicity, nutrition issues, and practical monitoring as CKD advances.
-
39:00
Legacy Drugs Still Bite
Metformin, sulfonylureas, and insulin in CKD, plus deprescribing when newer therapies are added.
-
49:00
Obesity Pharmacotherapy In CKD
Net benefit, hydration, sarcopenia, diuretic overlap, and who may be a poor fit despite BMI.
-
54:00
Case Review And Wrap
A structured medication review, recap of key prescribing moves, then Q&A and next-step takeaways.
Questions people ask before registering
-
It is designed for working professionals who make, support, or review medication decisions in CKD care. If renal dosing comes up in your day, you should feel at home.
-
No. We will use practical prescribing language and real cases. Familiarity with common diabetes and obesity medications helps, but no specialty fellowship is required.
-
It is case-based and practice-focused. You will see examples like SGLT2 use at low eGFR, GI illness on semaglutide, and hypoglycemia from older agents in CKD.
-
If the event team has enabled replay access, registrants typically receive it after the session. Check your registration details for the final attendance and replay terms.
-
Certificate and CE availability depend on the event setup. Review the registration page or confirmation email for the specific credit and documentation offered.